statistiche ricercatore

GROSSI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	7.098
EU - Europa	5.382
AS - Asia	4.708
SA - Sud America	606
Continente sconosciuto - Info sul continente non disponibili	543
AF - Africa	87
OC - Oceania	6
Totale	18.430

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	6.915
IT - Italia	3.392
SG - Singapore	2.130
CN - Cina	1.013
HK - Hong Kong	792
IE - Irlanda	574
BR - Brasile	501
VN - Vietnam	351
GB - Regno Unito	278
RU - Federazione Russa	244
FR - Francia	243
SE - Svezia	207
DE - Germania	157
FI - Finlandia	109
IN - India	81
CA - Canada	77
MX - Messico	74
BD - Bangladesh	73
JP - Giappone	42
IQ - Iraq	39
AR - Argentina	37
PL - Polonia	33
TR - Turchia	33
UA - Ucraina	29
ZA - Sudafrica	27
AT - Austria	26
NL - Olanda	26
ES - Italia	21
PK - Pakistan	18
SA - Arabia Saudita	18
EC - Ecuador	16
PH - Filippine	15
UZ - Uzbekistan	15
VE - Venezuela	15
ID - Indonesia	14
JO - Giordania	11
BE - Belgio	10
DZ - Algeria	10
KE - Kenya	9
LT - Lituania	9
TN - Tunisia	9
CL - Cile	8
CO - Colombia	8
EG - Egitto	8
MA - Marocco	8
PY - Paraguay	8
TH - Thailandia	8
AE - Emirati Arabi Uniti	7
JM - Giamaica	7
NG - Nigeria	7
MY - Malesia	6
UY - Uruguay	6
OM - Oman	5
PE - Perù	5
TT - Trinidad e Tobago	5
AU - Australia	4
CR - Costa Rica	4
EU - Europa	4
KZ - Kazakistan	4
MD - Moldavia	4
NP - Nepal	4
PA - Panama	4
AZ - Azerbaigian	3
CH - Svizzera	3
ET - Etiopia	3
IL - Israele	3
KG - Kirghizistan	3
NI - Nicaragua	3
PS - Palestinian Territory	3
PT - Portogallo	3
AL - Albania	2
AO - Angola	2
BG - Bulgaria	2
BO - Bolivia	2
BZ - Belize	2
GE - Georgia	2
GR - Grecia	2
GT - Guatemala	2
LB - Libano	2
NO - Norvegia	2
QA - Qatar	2
RS - Serbia	2
SV - El Salvador	2
SY - Repubblica araba siriana	2
TW - Taiwan	2
BB - Barbados	1
BH - Bahrain	1
BY - Bielorussia	1
CG - Congo	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DM - Dominica	1
DO - Repubblica Dominicana	1
GA - Gabon	1
HR - Croazia	1
KH - Cambogia	1
KI - Kiribati	1
KW - Kuwait	1
LA - Repubblica Popolare Democratica del Laos	1
ML - Mali	1
Totale	17.886

Salva come PNG Salva come JPEG

Città	#
Milan	2.466
San Jose	1.414
Singapore	1.115
Hong Kong	777
Ashburn	609
Dublin	574
Dallas	483
Princeton	435
The Dalles	305
Fairfield	300
Boardman	264
Beijing	247
Council Bluffs	242
Rome	230
Lauterbourg	218
Wilmington	199
Chicago	166
Nyköping	160
Chandler	131
Ho Chi Minh City	130
Santa Clara	116
San Diego	115
Woodbridge	112
London	111
Los Angeles	104
Seattle	100
Houston	93
Hanoi	88
Ogden	86
Helsinki	84
Cambridge	75
New York	69
Ann Arbor	56
São Paulo	53
Mexico City	46
Como	45
Orem	37
Munich	34
Tokyo	31
Warsaw	30
Guangzhou	29
Frankfurt am Main	28
Nuremberg	24
San Francisco	24
Brooklyn	23
Denver	23
Pune	23
Norwalk	22
Salt Lake City	22
Shanghai	22
Atlanta	20
Tampa	20
Da Nang	19
Hangzhou	19
Toronto	19
Chennai	18
Chiswick	18
Baghdad	17
Kilburn	16
Rio de Janeiro	16
Stockholm	16
Montreal	15
Phoenix	15
Turku	15
Vienna	15
Washington	15
Buffalo	14
Jacksonville	14
Johannesburg	14
Shenzhen	14
Zhengzhou	14
Boston	13
Redmond	13
Amsterdam	12
Las Vegas	12
Tashkent	12
Tianjin	12
Poplar	11
Wuhan	11
Amman	10
Belo Horizonte	10
Curitiba	10
Miami	10
Brussels	9
Dhaka	9
Düsseldorf	9
Elk Grove Village	9
Falkenstein	9
Genoa	9
Haiphong	9
Manchester	9
Ankara	8
Biên Hòa	8
Changsha	8
Nairobi	8
Nha Trang	8
Pittsburgh	8
Prescot	8
Saronno	8
Sterling	8
Totale	12.813

Salva come PNG Salva come JPEG

Nome	#
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin	178
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines.	173
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)	143
Afatinib for the treatment of non-small cell lung cancer	141
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis	130
Immune checkpoint inhibitors for treatment of small-cell lung cancer: a systematic review and meta-analysis	130
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy	121
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial	120
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study	119
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer	116
A review of clinical practice guidelines and treatment recommendations for cancer care in the COVID-19 pandemic	116
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	112
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer	112
DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer	108
Afatinib for the treatment of advanced non-small-cell lung cancer	107
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study	107
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines	105
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation	104
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019)	103
Novel treatment strategies for early-stage lung cancer: The oncologist’s perspective	102
Advances in treatment of mesothelioma	100
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial	100
Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy	98
Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients	98
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes	96
Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial	95
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial	95
Hematopoietic growth factors in lung cancer	95
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer	94
Liquid biopsy in non-small cell lung cancer: highlights and challenges	94
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer	92
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells	91
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial	91
Exosomes: a new horizon in lung cancer	90
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy	90
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	90
First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743	89
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)	89
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers	89
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects	88
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer	88
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine	87
Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study	86
Vinflunine for the treatment of non-small cell lung cancer	86
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial	86
Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib	86
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial	85
Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer	85
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study	84
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice?	84
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)	84
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds	84
Second-line Treatment of Advanced Non-small Cell Lung Cancer Non-oncogene Addicted: New Treatment Algorithm in the Era of Novel Immunotherapy	83
Successful treatment of lung adenocarcinoma with gefitinib based on EGFR gene amplification	83
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes from the Phase 3 KEYNOTE-189 Study	83
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab	83
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors	83
Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries	83
Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer	83
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib	83
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	83
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients	82
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis	82
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: A randomized study	82
Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries	82
Impact of low-dose computed tomography screening on lung cancer mortality among asbestos-exposed workers	81
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study	81
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer	81
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells	80
Ramucirumab: preclinical research and clinical development	80
The clinical management of early and advanced colorectal cancer	80
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study	79
Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy	79
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?	79
Impact of bmi on survival outcomes of immunotherapy in solid tumors: A systematic review	79
COVID-19 vaccination in patients with classic Kaposi’s sarcoma	79
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial	78
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients	78
Systemic drug therapy of malignant pleural mesothelioma.	78
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer	78
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition	78
IDH signalling pathway in cholangiocarcinoma: From biological rationale to therapeutic targeting	78
Triage process for the assessment of coronavirus disease 2019-positive patients with cancer: The ONCOVID prospective study	78
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases	77
NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer	77
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer	77
Looking for results in non-small-cell lung cancer: is bio-chemotherapy the right answer?	77
Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy	77
Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: can we use enemy territory at our advantage?	77
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG	77
Tag-based next generation sequencing: A feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients	77
Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy	76
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study	76
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	76
Integrated Somatic and Germline Whole-Exome Sequencing Analysis in Women with Lung Cancer after a Previous Breast Cancer	76
IL-12 Can Target Human Lung Adenocarcinoma Cells and Normal Bronchial Epithelial Cells Surrounding Tumor Lesions	75
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer.	75
Targeting kras in solid tumors: Current challenges and future opportunities of novel kras inhibitors	75
Trastuzumab deruxtecan: Changing the destiny of her2 expressing solid tumors	75
Update on the treatment of small cell lung cancer (SCLC)	75
Totale	9.130

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	140.729
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	140.729

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.833	0	5	1	0	430	190	192	151	232	186	105	341
2022/2023	1.155	225	49	70	40	78	310	4	69	84	176	16	34
2023/2024	3.882	483	689	646	787	905	116	26	52	146	12	3	17
2024/2025	3.119	17	29	584	41	37	221	101	99	499	220	208	1.063
2025/2026	8.048	393	647	495	975	549	327	1.902	513	1.055	566	327	299
2026/2027	221	190	31	0	0	0	0	0	0	0	0	0	0
Totale													18.430